LQDA (Liquidia) Net Current Asset Value: $0.45 (As of Mar. 2026) — 95% Below Median


LQDA Liquidia Corp LQDA
67 GF Score
Price $78.94
GF Value $226.87
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Liquidia Net Current Asset Value?

Liquidia LQDA -0.44% 67 Net Current Asset Value is $0.45 as of Mar. 2026, which is 95% below its 10-year median of 8.55. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $226.87 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 610 Drug Manufacturers companies, Liquidia ranks worse than 99.02% on this metric.

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Liquidia's net current asset value per share for the quarter that ended in Mar. 2026 was $0.45.

The historical rank and industry rank for Liquidia's Net Current Asset Value or its related term are showing as below:

LQDA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.25   Med: 8.55   Max: 175.43
Current: 175.42

During the past 10 years, the highest Price-to-Net-Current-Asset-Value Ratio of Liquidia was 175.43. The lowest was 3.25. And the median was 8.55.

LQDA's Price-to-Net-Current-Asset-Value is ranked worse than
99.02% of 610 companies
in the Drug Manufacturers industry
Industry Median: 5.745 vs LQDA: 175.42

Liquidia  (NAS:LQDA) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Liquidia Net Current Asset Value Related Terms


Liquidia Net Current Asset Value Historical Data

* Premium members only.

The historical data trend for Liquidia's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liquidia Net Current Asset Value Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.95 0.27 0.40 -0.11

Liquidia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.54 -0.31 -0.11 0.45

LQDA vs LNTH, HIMS, AMRX: Net Current Asset Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Liquidia's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Liquidia's Price-to-Net-Current-Asset-Value falls into.


LQDA
67GF Score
Liquidia Corp LQDA
Net Current Asset Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Liquidia Net Current Asset Value Calculation

Liquidia's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2025 is calculated as

Net Current Asset Value Per Share(A: Dec. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(273.401-283.186-0-0)/87.204
=-0.11

Liquidia's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2026 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2026 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(333.055-292.954-0-0)/88.308
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Current Asset Value of $0.45 mean?
Liquidia (LQDA) has a Net Current Asset Value of $0.45 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Liquidia and its competitors. This is 95% below median its historical median of 8.55. Over the past decade, Liquidia's Net Current Asset Value has ranged from 3.25 to 175.43. According to the industry distribution chart, Liquidia ranks #604 out of 610 companies in the Drug Manufacturers industry, placing it in the top 99%.
Is Liquidia's Net Current Asset Value too high?
Liquidia's current Net Current Asset Value of $0.45 is 95% below median its 10-year median of 8.55. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 175.43. The Drug Manufacturers industry median Net Current Asset Value is 5.75. Liquidia's value of $0.45 is 92.2% below this industry median. Based on the distribution chart, Liquidia ranks #604 out of 610 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's Net Current Asset Value compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #604 out of 610 companies for Net Current Asset Value. This places Liquidia in the lower half of its industry. The industry median Net Current Asset Value is 5.75. Liquidia's value of $0.45 is 92.2% below this benchmark. Historically, Liquidia's own Net Current Asset Value has ranged from 3.25 to 175.43 over the past decade. While the company's 10-year median is 8.55 vs. the industry median of 5.75, Liquidia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.75, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current Net Current Asset Value of $0.45 is 92.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Liquidia and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current Net Current Asset Value is $0.45, which is 95% below median its own 10-year median of 8.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $226.87, compared to a current price of $78.94 — trading 65.2% below its estimated fair value. The current Net Current Asset Value is $0.45, which is 95% below median its 10-year median of 8.55 and 92.2% below the Drug Manufacturers industry median of 5.75. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Liquidia (LQDA), the current Net Current Asset Value is $0.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Liquidia (LQDA) Overvalued in 2026?

Based on GuruFocus' analysis, Liquidia stock appears to be undervalued. The current stock price of $78.94 is trading 65.2% below its estimated GF Value™ of $226.87. GuruFocus considers Liquidia to be Possible Value Trap.

Key valuation signals for LQDA:

  • Net Current Asset Value: $0.45 (95% below median its 10-year median of 8.55)
  • GF Value™: $226.87 vs. price of $78.94 (65.2% below fair value)
  • GF Score™: 67/100 with 6 warning signs
  • Industry Position: 92.2% below the Drug Manufacturers median (#604 of 610)

No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Liquidia Business Description

Other Exchanges LT4:Germany
Address 419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score

Get the complete analysis for LQDA

Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$78.94
Price
$226.87
GF Value